BAP1 and gastric adenocarcinoma: Reduced BAP1 expression has been linked to poor prognosis and adverse tumor features in renal carcinoma [10–12], colorectal cancer [34], gastric adenocarcinoma [35], non-small cell lung cancer [8, 9], gall bladder cancer [13] and uveal melanoma [16–18, 36].